# Lecture 04: Hemoglobinopathies ## Unit 2.9: Hematology and Oncology --- ## Learning Objectives By the end of this lecture, students will be able to: 1. Describe normal hemoglobin structure and developmental changes 2. Explain the pathophysiology of sickle cell disease 3. Describe the clinical manifestations and complications of sickle cell disease 4. Explain the classification and types of thalassemia 5. Describe the clinical features and treatment of thalassemia 6. Explain hemoglobin electrophoresis and other diagnostic tests --- ## Lecture Outline ### I. Normal Hemoglobin Structure Hemoglobin is a tetrameric protein optimized for oxygen transport, consisting of four globin chains each containing a heme prosthetic group with a central iron atom. The quaternary structure allows cooperative oxygen binding, where binding of the first oxygen molecule increases affinity for subsequent molecules, producing the characteristic sigmoidal oxygen dissociation curve. This cooperativity enables efficient oxygen loading in the lungs where partial pressure is high and oxygen release in tissues where partial pressure is low. The iron must remain in the ferrous state to reversibly bind oxygen; oxidation to the ferric state produces methemoglobin incapable of oxygen transport. The heme group consists of protoporphyrin IX coordinated with a ferrous iron atom positioned to bind oxygen reversibly. Each globin chain wraps around its heme group in a hydrophobic pocket that protects the iron from oxidation while allowing oxygen access. The four heme groups in the hemoglobin tetramer can each bind one oxygen molecule, allowing each hemoglobin to transport up to four oxygen molecules. The interaction between chains creates allosteric effects where conformational changes from oxygen binding at one site increase oxygen affinity at other sites. This cooperativity is essential for hemoglobin's physiologic function, distinguishing it from myoglobin which lacks cooperativity and serves primarily for oxygen storage in muscle. Normal adult hemoglobin exists in several forms distinguished by their globin chain composition. Hemoglobin A, comprising two alpha chains and two beta chains designated alpha-2-beta-2, constitutes approximately 97 percent of adult hemoglobin. Hemoglobin A2, consisting of two alpha and two delta chains, accounts for 2 to 3 percent and is clinically important in diagnosing beta-thalassemia trait. Fetal hemoglobin containing two alpha and two gamma chains normally falls below 1 percent in adults but has higher oxygen affinity than hemoglobin A, facilitating oxygen transfer from maternal to fetal circulation. The gamma chains of fetal hemoglobin bind 2,3-diphosphoglycerate less avidly than beta chains, explaining the higher oxygen affinity that enables oxygen extraction from maternal blood. Globin gene organization underlies the developmental regulation and inherited disorders of hemoglobin production. The alpha-globin gene cluster on chromosome 16 contains two alpha genes per chromosome, providing four total copies that produce alpha chains throughout life from early embryonic development. The beta-globin gene cluster on chromosome 11 contains epsilon, gamma, delta, and beta genes arranged in their order of developmental expression. Embryonic hemoglobins contain epsilon and zeta chains, fetal hemoglobin contains gamma chains, and adult hemoglobins contain delta and beta chains. Hemoglobin switching during development silences gamma gene expression while activating delta and beta genes, explaining why hemoglobinopathies affecting beta chains manifest after birth as fetal hemoglobin declines during the first six months of life. Panel A: Three-dimensional structure of hemoglobin tetramer showing alpha and beta chains arranged around central cavity with heme groups positioned in hydrophobic pockets. Panel B: Oxygen-hemoglobin dissociation curve demonstrating sigmoidal shape with P50 marked and factors causing rightward or leftward shifts including pH, temperature, and 2,3-DPG. Panel C: Diagram of chromosome 16 alpha-globin gene cluster and chromosome 11 beta-globin gene cluster showing gene arrangement and developmental expression patterns. Panel D: Pie chart showing relative proportions of hemoglobin A at 97 percent, A2 at 2-3 percent, and fetal hemoglobin below 1 percent in normal adults. --- ### II. Sickle Cell Disease Genetics and Pathophysiology Sickle cell disease results from homozygosity for the sickle mutation, a single nucleotide substitution in the beta-globin gene causing valine to replace glutamic acid at position 6 of the beta chain. The codon change from GAG to GTG creates this amino acid substitution through a single point mutation inherited in autosomal recessive fashion. This seemingly minor change has profound consequences because the hydrophobic valine residue creates a sticky patch on the deoxyhemoglobin surface that fits into a complementary pocket on adjacent hemoglobin molecules. When hemoglobin releases oxygen and converts to the deoxygenated form, these interactions cause hemoglobin molecules to polymerize into long rigid fibers within the red blood cell, distorting the normally flexible biconcave disc into the characteristic elongated sickle shape. The geographic distribution of sickle cell disease reflects the heterozygote advantage conferred by sickle trait against Plasmodium falciparum malaria. Individuals carrying one sickle gene have partial protection against severe malaria through mechanisms including enhanced clearance of parasitized cells and reduced parasite growth. This selective advantage maintains high gene frequency in endemic regions including sub-Saharan Africa, the Mediterranean basin, the Middle East, and the Indian subcontinent. In the United States, approximately 100,000 individuals are affected, and universal newborn screening programs enable early identification and initiation of preventive care. The public health impact extends beyond those with disease to the approximately 3 million Americans with sickle cell trait who may transmit the gene to offspring. The kinetics of hemoglobin polymerization determine clinical severity and therapeutic targets. Polymerization occurs only when hemoglobin is deoxygenated and requires a critical concentration of sickle hemoglobin to proceed. Initial polymerization is relatively slow, providing a delay period during which red cells can traverse capillaries and reoxygenate before sickling occurs. If transit time through the microvasculature exceeds this delay period, sickling occurs within vessels, causing vaso-occlusion. Factors reducing the delay period include high sickle hemoglobin concentration, low oxygen tension, acidosis, and dehydration. Fetal hemoglobin does not participate in polymer formation and effectively dilutes sickle hemoglobin, explaining why patients with hereditary persistence of fetal hemoglobin have milder disease. Multiple genotypes produce sickle cell disease phenotypes with varying clinical severity. Homozygous sickle cell anemia with two copies of the sickle gene produces the most severe disease with greater than 80 percent sickle hemoglobin. Sickle-hemoglobin C disease results from compound heterozygosity for sickle and hemoglobin C mutations, producing moderate disease with some complications occurring more frequently including retinopathy. Sickle-beta-zero thalassemia with complete absence of normal beta-globin from the thalassemic chromosome produces severity similar to homozygous disease. Sickle-beta-plus thalassemia with reduced but present beta-globin production allows some hemoglobin A formation and produces milder disease. Sickle cell trait with approximately 40 percent sickle hemoglobin and 60 percent hemoglobin A rarely causes symptoms under normal conditions. Panel A: Molecular diagram showing the sickle mutation with valine replacing glutamic acid at beta-6 position and the resulting hydrophobic interaction causing hemoglobin polymerization in deoxygenated state. Panel B: World map indicating geographic distribution of sickle cell disease and trait prevalence correlating with historical malaria endemicity in Africa, Mediterranean, Middle East, and India. Panel C: Comparison of hemoglobin polymerization kinetics showing delay time affected by sickle hemoglobin concentration, oxygen tension, pH, and dehydration. Panel D: Inheritance diagram showing outcomes from sickle trait parents including normal, trait, and disease offspring with 25 percent probability each. --- ### III. Sickle Cell Disease Pathophysiology Mechanisms Vaso-occlusion represents the primary pathophysiologic mechanism directly causing the painful crises and organ damage characteristic of sickle cell disease. Beyond simple mechanical obstruction by rigid sickled cells, vaso-occlusion involves complex interactions between sickle red cells, white blood cells, platelets, and the activated endothelium. Sickled cells adhere to endothelial cells through multiple adhesion molecules upregulated by inflammation and hemolysis-induced endothelial activation. Adherent red cells slow blood flow, prolonging local transit time and promoting further sickling in a vicious cycle of obstruction and ischemia. Activated neutrophils and platelets participate in these interactions, explaining why infections commonly precipitate vaso-occlusive crises by amplifying the inflammatory component. Hemolysis in sickle cell disease results from the shortened survival of abnormal red blood cells and contributes to chronic anemia and disease complications. Repeated cycles of sickling and unsickling damage the red cell membrane, eventually producing irreversibly sickled cells that retain their abnormal shape even when reoxygenated. These rigid cells have markedly shortened survival, typically 10 to 20 days compared to the normal 120 days, producing chronic hemolytic anemia with baseline hemoglobin typically 6 to 10 grams per deciliter. Both extravascular hemolysis through splenic sequestration and intravascular hemolysis through direct cell lysis contribute to red cell destruction. Chronic hemolysis causes unconjugated hyperbilirubinemia leading to pigmented gallstones, and ongoing iron release contributes to iron overload in chronically transfused patients. Nitric oxide depletion from intravascular hemolysis produces important vasculopathic consequences affecting multiple organ systems. Free hemoglobin released into plasma rapidly scavenges nitric oxide, the major endothelium-derived vasodilator and inhibitor of platelet aggregation. Additionally, arginase released from lysed red cells depletes arginine, the substrate for nitric oxide synthesis. Reduced nitric oxide bioavailability causes vasoconstriction, endothelial activation, and a procoagulant state. These mechanisms contribute to pulmonary hypertension, priapism, and leg ulcers, complications particularly associated with the hemolytic phenotype. Understanding this pathway has led to investigation of nitric oxide donors and phosphodiesterase inhibitors as potential therapeutic approaches. Factors promoting sickling events help identify triggers that patients should avoid and inform management strategies. Hypoxia directly promotes deoxygenation of hemoglobin and thus polymerization, making high altitude, hypoventilation, and respiratory illness particularly dangerous. Dehydration increases intracellular hemoglobin concentration, shortening the delay period and accelerating polymerization. Acidosis right-shifts the oxygen dissociation curve, promoting oxygen release and deoxygenation at any given oxygen tension. Fever increases metabolic oxygen demand while infection-related inflammation activates the endothelium and promotes adhesion. Cold exposure causes vasoconstriction, slowing blood flow and prolonging capillary transit time. Stress activates catecholamines causing similar vasoconstriction. Recognizing and addressing these factors forms the basis of preventive care and acute crisis management. Panel A: Illustration of vaso-occlusion mechanism showing sickled cells adhering to activated endothelium with neutrophil and platelet involvement creating microvessel obstruction and ischemia. Panel B: Comparison of normal red cell transit through capillary versus sickled cell causing occlusion with surrounding tissue ischemia. Panel C: Nitric oxide depletion pathway showing hemolysis releasing free hemoglobin that scavenges nitric oxide and arginase that depletes arginine substrate. Panel D: Diagram of factors promoting sickling including hypoxia, dehydration, acidosis, infection, and cold with corresponding preventive strategies. --- ### IV. Sickle Cell Disease Clinical Manifestations Acute vaso-occlusive pain crisis represents the hallmark clinical manifestation of sickle cell disease, causing recurrent episodes of severe pain that significantly impact quality of life. Pain typically affects the bones, chest, abdomen, or any vascular bed where sickling causes tissue ischemia, with bone pain being most common, particularly affecting the long bones, spine, and pelvis. Episodes may be triggered by infection, dehydration, cold exposure, stress, or high altitude, though many occur without identifiable precipitant. Pain intensity is severe, often described as excruciating, requiring opioid analgesia for adequate management. Duration ranges from hours to weeks, with most crises resolving within five to seven days. Frequency varies enormously between patients, from none to frequent hospitalizations, with pain frequency being the primary driver of healthcare utilization and disability. Acute chest syndrome represents a life-threatening pulmonary complication defined by new pulmonary infiltrate with respiratory symptoms including fever, cough, chest pain, or hypoxia. The pathophysiology involves pulmonary vaso-occlusion from in situ sickling, fat embolism from infarcted bone marrow releasing fat particles into the venous circulation, and infection often occurring in combination. Chest syndrome is the leading cause of death in adult sickle cell patients and requires aggressive management including supplemental oxygen to maintain saturation, incentive spirometry to prevent atelectasis, pain control sufficient to enable deep breathing, and empiric antibiotics covering typical and atypical respiratory pathogens. Simple transfusion to raise hemoglobin or exchange transfusion to reduce sickle hemoglobin percentage may be required for moderate to severe cases. Stroke occurs in approximately 11 percent of patients with sickle cell disease by age 20, resulting from stenosis or occlusion of the internal carotid or middle cerebral arteries. Ischemic stroke is more common in children, while hemorrhagic stroke predominates in adults, though both types occur at all ages. Ischemic stroke presents with acute focal neurologic deficits and requires emergent exchange transfusion to reduce sickle hemoglobin percentage below 30 percent. Transcranial Doppler ultrasound screening from ages 2 to 16 identifies children at high risk for stroke by detecting elevated flow velocities indicating arterial stenosis. Chronic transfusion therapy maintaining sickle hemoglobin below 30 percent dramatically reduces stroke risk in high-risk children and is continued indefinitely to prevent recurrence after an initial event. Infections represent a major cause of morbidity and mortality, particularly in young children, due to functional asplenia developing early in childhood. Repeated vaso-occlusive episodes cause progressive splenic infarction and fibrosis, eliminating the spleen's ability to filter encapsulated bacteria typically by age 5. Streptococcus pneumoniae sepsis historically caused high mortality in young children, now substantially reduced by penicillin prophylaxis from infancy through at least age 5 and comprehensive pneumococcal vaccination including both conjugate and polysaccharide vaccines. Osteomyelitis, particularly from Salmonella species and Staphylococcus aureus, affects bones with prior infarction. Acute splenic sequestration, occurring before complete autosplenectomy, causes sudden pooling of blood in the spleen with rapid hemoglobin drop and hypovolemic shock, requiring emergent transfusion and sometimes splenectomy. Panel A: Human body diagram indicating sites of vaso-occlusive pain including bones, joints, chest, and abdomen with associated complications at each anatomic location. Panel B: Chest radiograph demonstrating bilateral pulmonary infiltrates characteristic of acute chest syndrome with diagnostic criteria listed. Panel C: Brain MRI showing ischemic stroke in middle cerebral artery distribution with transcranial Doppler screening illustration. Panel D: Timeline of splenic function loss from early childhood with functional asplenia by age 5 showing associated infection risks and preventive measures. --- ### V. Sickle Cell Disease Chronic Complications Chronic organ damage accumulates progressively from recurrent vaso-occlusion and hemolysis, affecting nearly every organ system and reducing life expectancy despite advances in comprehensive care. Pulmonary complications include chronic lung disease from recurrent acute chest syndrome episodes and pulmonary hypertension from hemolysis-induced nitric oxide depletion and chronic thromboembolic disease. Pulmonary hypertension carries poor prognosis and should be screened for with echocardiography, with elevated tricuspid regurgitant jet velocity prompting further evaluation. Cardiac complications include diastolic dysfunction from chronic anemia and iron overload in transfused patients. Renal complications progress through characteristic stages requiring monitoring and intervention. Sickle cell nephropathy progresses through recognizable stages reflecting the unique effects of sickling in the renal medulla. The hypertonic, hypoxic, acidic medullary environment promotes sickling in the vasa recta, impairing the countercurrent mechanism and causing early hyposthenuria with inability to concentrate urine. Papillary necrosis from medullary infarction causes gross or microscopic hematuria. Glomerular hyperfiltration occurs as an early compensatory response to anemia, eventually leading to focal segmental glomerulosclerosis with proteinuria. Progressive decline in glomerular filtration rate leads to end-stage renal disease in up to 20 percent of adults. ACE inhibitors may slow progression in patients with proteinuria, and renal replacement therapy including dialysis and transplantation is available for end-stage disease. Avascular necrosis of the femoral and humeral heads results from bone infarction, causing chronic pain and disability often requiring joint replacement. The femoral head is most commonly affected, presenting with hip pain and limited range of motion, diagnosed by MRI showing characteristic changes before plain radiograph abnormalities appear. Proliferative retinopathy develops from retinal ischemia and can cause visual loss without regular ophthalmologic screening and treatment with laser photocoagulation for neovascularization. Leg ulcers develop around the ankles, typically over the malleoli, and are difficult to heal due to local vaso-occlusion impairing tissue perfusion, requiring aggressive local wound care and sometimes transfusion therapy. Priapism, painful prolonged erection from vaso-occlusion in the corpora cavernosa, may be stuttering with recurrent brief episodes or major lasting more than 4 hours requiring urologic intervention. Life expectancy in sickle cell disease has improved substantially with comprehensive care but remains reduced compared to the general population. Median survival has increased from approximately 14 years in the pre-antibiotic era to over 50 years currently in high-resource settings with access to comprehensive care. Leading causes of death in adults include pulmonary hypertension, renal failure, acute chest syndrome, and infection. Quality of life measures show significant impairment from chronic pain, fatigue, and the psychological burden of a chronic life-threatening illness. Transition from pediatric to adult care represents a particularly vulnerable period when healthcare engagement often declines. Comprehensive sickle cell centers providing multidisciplinary care with hematology, pain management, nephrology, cardiology, and psychosocial support optimize outcomes. Panel A: Multi-organ diagram showing chronic complications including stroke, pulmonary hypertension, cardiomegaly, nephropathy, leg ulcers, and avascular necrosis with arrows indicating disease progression over time. Panel B: Hip MRI demonstrating avascular necrosis of the femoral head with characteristic signal changes and staging description. Panel C: Fundoscopic photograph showing proliferative retinopathy with sea-fan neovascularization requiring treatment. Panel D: Graph showing improvement in median life expectancy over decades from 1970s to present with timeline of major therapeutic advances. --- ### VI. Sickle Cell Disease Treatment General management of sickle cell disease includes preventive measures and supportive care forming the foundation upon which disease-modifying therapies are added. Penicillin prophylaxis beginning at two months of age and continuing until at least age 5 prevents pneumococcal sepsis in functionally asplenic children, representing one of the most important interventions improving childhood survival. Comprehensive vaccination including pneumococcal conjugate and polysaccharide vaccines, meningococcal vaccines, and Haemophilus influenzae type b vaccine addresses the infection susceptibility. Daily folic acid supplementation supports the increased erythropoietic demands of chronic hemolytic anemia. Maintaining adequate hydration helps prevent dehydration-induced sickling. Regular screening for complications including transcranial Doppler for stroke risk, ophthalmologic examination for retinopathy, and echocardiography for pulmonary hypertension enables early intervention. Acute pain management requires aggressive opioid analgesia with a patient-centered approach recognizing that pain is often undertreated due to unfounded concerns about addiction and drug-seeking behavior. Initial assessment should evaluate pain severity using standardized scales, potential triggers including infection and dehydration, and complications requiring specific treatment. Parenteral opioids, typically morphine or hydromorphone, provide first-line analgesia, with patient-controlled analgesia offering advantages for moderate to severe pain. Non-steroidal anti-inflammatory drugs and acetaminophen serve as adjuncts to opioids. Hydration with hypotonic intravenous fluids corrects dehydration contributing to sickling without causing volume overload. Incentive spirometry every 2 hours while awake prevents the atelectasis that precipitates acute chest syndrome. Pain reassessment should guide titration, with transition to oral opioids as pain improves. Hydroxyurea represents the primary disease-modifying therapy for sickle cell disease, providing benefit through multiple mechanisms. The principal effect is induction of fetal hemoglobin, which does not participate in polymer formation and effectively reduces intracellular sickle hemoglobin concentration, lengthening the delay period before sickling occurs. Additional mechanisms include improved red cell hydration and decreased expression of adhesion molecules reducing vaso-occlusion. Clinical benefits demonstrated in randomized trials include reduced frequency of pain crises, fewer episodes of acute chest syndrome, decreased transfusion requirements, and improved survival. Hydroxyurea is now recommended for essentially all patients with sickle cell disease starting in childhood, titrated to maximum tolerated dose based on response and monitoring for myelosuppression with regular complete blood counts. Transfusion therapy provides both acute management of complications and chronic prevention of recurrent events. Simple transfusion raising hemoglobin to approximately 10 grams per deciliter improves oxygen-carrying capacity and reduces sickle hemoglobin percentage through dilution. Exchange transfusion more rapidly reduces sickle hemoglobin percentage by removing patient blood while simultaneously transfusing normal red cells, indicated for severe acute complications including stroke, severe acute chest syndrome, and multiorgan failure. Chronic transfusion maintaining sickle hemoglobin below 30 percent prevents primary and secondary stroke in high-risk children and is used for prevention of recurrent complications when other therapies fail. Complications of chronic transfusion include alloimmunization complicating future transfusion matching and iron overload requiring chelation therapy with deferasirox or deferoxamine. Panel A: Flowchart for acute pain crisis management showing initial assessment, analgesia protocol with opioid dosing, supportive care including hydration and incentive spirometry, and criteria for escalation. Panel B: Mechanism of hydroxyurea action showing fetal hemoglobin induction reducing polymer formation, improved red cell hydration, and reduced adhesion molecule expression. Panel C: Diagram comparing simple transfusion versus exchange transfusion showing hemoglobin composition and sickle percentage before and after each procedure. Panel D: Timeline of therapeutic advances from penicillin prophylaxis through hydroxyurea to newer agents including voxelotor, crizanlizumab, and gene therapy approaches. --- ### VII. Thalassemia Overview and Pathophysiology Thalassemia syndromes result from mutations that reduce or eliminate production of alpha or beta globin chains, creating imbalance between alpha and beta chain synthesis. Unlike structural hemoglobinopathies where abnormal hemoglobin is produced, thalassemias produce reduced quantities of normal chains or no chains at all from affected genes. The excess unpaired chains precipitate within erythroid precursors, causing oxidative damage, membrane injury, and premature cell death, producing ineffective erythropoiesis where most developing red cells die in the bone marrow before reaching circulation. Clinical severity ranges from asymptomatic carrier states to lethal conditions depending on the number and severity of genes affected. Thalassemias are most common in the Mediterranean region, Middle East, Africa, and Southeast Asia, with carrier frequency reaching 20 percent in some populations reflecting heterozygote protection against malaria similar to sickle trait. Alpha-thalassemia results from deletion or dysfunction of alpha-globin genes, with clinical severity directly related to the number of affected genes. The alpha-globin gene cluster on chromosome 16 contains two alpha genes per chromosome, providing four total alpha genes. Silent carrier state with one gene affected produces no hematologic abnormality and is clinically undetectable. Alpha-thalassemia trait with two genes affected causes mild microcytosis often mistaken for iron deficiency but requires no treatment. Hemoglobin H disease with three genes affected produces moderate hemolytic anemia from accumulation of beta-chain tetramers called hemoglobin H. Hemoglobin Barts hydrops fetalis with all four genes deleted is incompatible with extrauterine life, as no alpha chains are available to form any functional hemoglobin after the embryonic period, causing severe fetal anemia and death. Beta-thalassemia results from point mutations in the beta-globin gene that reduce (beta-plus) or eliminate (beta-zero) chain production. Over 200 mutations have been described with varying effects on gene expression, including promoter mutations, splice site mutations, and nonsense mutations. Beta-thalassemia minor, the heterozygous carrier state, produces mild microcytic anemia with elevated hemoglobin A2 on electrophoresis but no transfusion requirement. Beta-thalassemia intermedia represents moderate disease requiring intermittent transfusion for complications or severe anemia. Beta-thalassemia major, usually resulting from homozygosity or compound heterozygosity for severe mutations, produces transfusion-dependent anemia presenting in infancy as fetal hemoglobin declines. The severity depends on the specific mutations inherited and coinheritance of genetic modifiers affecting fetal hemoglobin production. The pathophysiology of thalassemia involves both ineffective erythropoiesis and hemolysis contributing to severe anemia. In beta-thalassemia, excess alpha chains that cannot find beta partners precipitate in erythroid precursors, causing membrane damage and intramedullary destruction before cells can mature. Erythropoietin production increases massively in response to anemia, driving marrow expansion that causes skeletal deformities if untreated. The few red cells reaching circulation are abnormal with damaged membranes and have shortened survival, adding extravascular hemolysis to the ineffective erythropoiesis. Massive marrow expansion in untreated disease causes frontal bossing, maxillary hypertrophy producing "chipmunk facies," and cortical thinning of bones with pathologic fractures. Iron absorption increases inappropriately due to suppressed hepcidin despite iron overload, compounding the iron loading from chronic transfusion. Panel A: Diagram showing alpha and beta globin chain synthesis with normal balanced production versus thalassemic imbalanced production with excess unpaired chains precipitating. Panel B: Comparison of normal erythropoiesis versus thalassemic ineffective erythropoiesis showing alpha chain precipitation in erythroid precursors and intramedullary hemolysis. Panel C: World map indicating geographic distribution of alpha thalassemia and beta thalassemia with carrier frequencies in Mediterranean, Middle East, Africa, and Southeast Asia. Panel D: Clinical spectrum diagram ranging from silent carrier through trait, intermedia, to major with corresponding severity and treatment requirements. --- ### VIII. Alpha and Beta Thalassemia Clinical Syndromes Alpha-thalassemia genotype-phenotype correlations follow predictable patterns based on the number of functional alpha genes remaining. With one gene deleted from the normal four, silent carrier status produces no detectable hematologic abnormality and can only be diagnosed by molecular testing. With two genes deleted, alpha-thalassemia trait produces mild microcytosis with MCV typically 65 to 75 femtoliters but minimal or no anemia, often discovered incidentally during routine screening. The two-gene deletion can occur in cis (both deletions on one chromosome) or trans (one deletion on each chromosome), which matters for genetic counseling since cis carriers risk having offspring with hemoglobin H disease or Barts hydrops. With three genes deleted, hemoglobin H disease produces moderate hemolytic anemia with hemoglobin 7 to 10 grams per deciliter, splenomegaly, and complications from chronic hemolysis. Hemoglobin H disease requires understanding for appropriate management of this intermediate severity alpha-thalassemia syndrome. The single remaining alpha gene produces only about one-quarter of normal alpha-chain output, leading to marked beta-chain excess. Beta-4 tetramers called hemoglobin H form spontaneously, producing inclusions visible on supravital staining as "golf-ball" cells. Hemoglobin H has very high oxygen affinity and is functionally useless for oxygen delivery, contributing to symptoms beyond what the hemoglobin level alone would suggest. Most patients do not require regular transfusion but may need intermittent transfusion during hemolytic crises triggered by infection or oxidant drugs. Management includes folic acid supplementation, avoidance of oxidant medications similar to G6PD deficiency, and regular monitoring for complications including splenomegaly and iron overload. Beta-thalassemia major presents in infancy as fetal hemoglobin production declines and the absence of beta chains becomes apparent. Affected infants appear normal at birth when fetal hemoglobin predominates, then develop progressive anemia, failure to thrive, and hepatosplenomegaly during the first year of life. Without treatment, massive erythroid hyperplasia causes the classic thalassemic facies with frontal bossing from skull marrow expansion, prominent malar eminences, and dental malocclusion from maxillary overgrowth. The "hair-on-end" appearance on skull radiographs reflects massive marrow expansion with trabecular bone formation. Extramedullary hematopoiesis produces hepatosplenomegaly and paraspinal masses. Severe anemia leads to high-output cardiac failure. Death typically occurs in the first few years of life without transfusion therapy. Beta-thalassemia trait produces characteristic laboratory findings that must be distinguished from iron deficiency anemia. Hemoglobin is mildly reduced, typically 9 to 11 grams per deciliter. The hallmark finding is marked microcytosis with MCV often 60 to 70 femtoliters, disproportionate to the mild anemia. Red blood cell count is normal or elevated as smaller cells are produced more readily, contributing to the useful Mentzer index where MCV divided by RBC count below 13 suggests thalassemia and above 13 suggests iron deficiency. Hemoglobin electrophoresis shows elevated hemoglobin A2 between 3.5 and 7 percent, the key diagnostic finding distinguishing beta-thalassemia trait from iron deficiency. Iron studies are normal, and inappropriately prescribing iron to patients misdiagnosed with iron deficiency may cause harm through iron accumulation. Panel A: Alpha-thalassemia genotype-phenotype correlation diagram showing normal four genes through progressive deletions to silent carrier, trait, HbH disease, and Barts hydrops with clinical severity at each level. Panel B: Peripheral blood smear from hemoglobin H disease showing microcytosis, hypochromia, and target cells with supravital stain inset demonstrating characteristic HbH inclusions. Panel C: Clinical photograph showing thalassemic facies with frontal bossing, prominent cheekbones, and dental malocclusion from marrow expansion in untreated beta-thalassemia major. Panel D: Skull radiograph demonstrating "hair-on-end" appearance from massive marrow expansion in thalassemia major. --- ### IX. Thalassemia Treatment Chronic transfusion therapy forms the cornerstone of management for beta-thalassemia major, suppressing ineffective erythropoiesis and preventing complications of severe anemia. The goal is maintaining pre-transfusion hemoglobin above 9 to 10.5 grams per deciliter, which adequately suppresses erythropoietin drive and prevents marrow expansion while avoiding cardiac complications of severe anemia. Regular transfusions typically every 2 to 4 weeks achieve these goals. Packed red blood cells should be leukoreduced to prevent febrile reactions, CMV transmission, and alloimmunization. Phenotypically matched units for Rh and Kell antigens reduce alloimmunization risk, important given lifelong transfusion requirements. Despite these measures, iron overload from repeated transfusions inevitably develops and eventually exceeds the body's limited excretion capacity, making iron chelation an essential component of therapy. Iron overload from chronic transfusion causes progressive organ damage that becomes the major determinant of morbidity and mortality in adequately transfused patients. Each unit of transfused red cells contains approximately 200 to 250 milligrams of iron with no physiologic mechanism for excretion. Iron deposits first in the liver, causing fibrosis progressing to cirrhosis. Cardiac iron deposition causes cardiomyopathy that was historically the leading cause of death before effective chelation was available. Endocrine iron deposition causes hypogonadotropic hypogonadism with delayed puberty and infertility, diabetes mellitus, hypothyroidism, and hypoparathyroidism. Monitoring with serum ferritin every 3 months, liver MRI for hepatic iron quantification, and cardiac MRI T2-star for cardiac iron assessment guides chelation intensity. Maintaining ferritin below 1000 nanograms per milliliter and liver iron concentration below 5 milligrams per gram dry weight prevents complications. Iron chelation therapy removes excess iron to prevent and reverse organ damage using agents with different administration routes and toxicity profiles. Deferoxamine was the first available chelator, requiring prolonged subcutaneous or intravenous infusion typically 8 to 12 hours daily, 5 to 7 days weekly due to its short half-life. This demanding regimen limits adherence, particularly during adolescence. Deferasirox is an oral chelator taken once daily, dramatically improving convenience and compliance and representing the most commonly used agent currently. Deferiprone is another oral option particularly effective at removing cardiac iron and sometimes used in combination with deferoxamine for severe cardiac iron overload. All chelators have significant toxicity profiles requiring monitoring, including nephrotoxicity and gastrointestinal effects with deferasirox, and agranulocytosis risk with deferiprone requiring regular blood counts. Curative therapies offer the possibility of eliminating the need for lifelong transfusion and chelation. Hematopoietic stem cell transplantation from a matched sibling donor in young patients without significant iron-related organ damage achieves cure rates exceeding 90 percent, replacing defective marrow with normal donor-derived hematopoiesis. Outcomes decline with increasing age, iron burden, and hepatomegaly at transplant. Matched unrelated donor and haploidentical transplant protocols have expanded options for patients without matched siblings. Gene therapy using autologous stem cells modified to add a functional beta-globin gene or reactivate fetal hemoglobin has achieved FDA approval with betibeglogene autotemcel, offering cure without donor requirement. Luspatercept, an erythroid maturation agent, reduces transfusion burden in some patients by improving ineffective erythropoiesis, representing a new therapeutic approach for those unable to undergo curative therapies. Panel A: Transfusion protocol diagram showing target hemoglobin goals, typical frequency, and monitoring parameters for beta-thalassemia major management. Panel B: Cardiac MRI T2-star image demonstrating myocardial iron deposition with signal loss and corresponding T2-star value indicating iron overload severity. Panel C: Comparison of iron chelation regimens showing deferoxamine infusion, deferasirox tablets, and deferiprone with dosing, advantages, disadvantages, and required monitoring for each. Panel D: Treatment algorithm showing progression from transfusion and chelation through splenectomy indications to curative options including transplant and gene therapy. --- ### X. Diagnosis and Genetic Counseling Hemoglobin electrophoresis and high-performance liquid chromatography provide definitive diagnosis and characterization of hemoglobin variants and thalassemias. Standard electrophoresis separates hemoglobins based on charge at alkaline or acidic pH, while isoelectric focusing provides higher resolution separation. HPLC separates hemoglobins based on interaction with column material, providing quantitation of each hemoglobin fraction. Normal adult patterns show hemoglobin A at approximately 97 percent, hemoglobin A2 at 2 to 3 percent, and fetal hemoglobin below 1 percent. Sickle cell trait shows approximately 55 to 60 percent hemoglobin A and 40 to 45 percent hemoglobin S. Sickle cell disease shows greater than 80 percent hemoglobin S with absent hemoglobin A. Beta-thalassemia trait shows elevated hemoglobin A2 between 3.5 and 7 percent, the key distinguishing feature from iron deficiency. Iron studies differentiation is critical because thalassemia trait and iron deficiency anemia produce similar microcytic patterns but require opposite treatments. Iron deficiency shows low serum iron, elevated total iron-binding capacity, low transferrin saturation, and low ferritin reflecting depleted stores. Thalassemia trait shows normal or elevated serum iron, normal total iron-binding capacity, normal or elevated ferritin reflecting adequate or increased stores. Prescribing iron to a patient with thalassemia trait misdiagnosed as iron deficient provides no benefit and may cause harm through iron accumulation. The Mentzer index offers a simple screening tool, with MCV divided by RBC count below 13 suggesting thalassemia and above 13 suggesting iron deficiency, though the sensitivity and specificity are imperfect and definitive testing should follow. Newborn screening programs enable early identification of sickle cell disease and other clinically significant hemoglobinopathies, allowing initiation of preventive care before complications develop. All US states perform universal newborn screening using hemoglobin electrophoresis or HPLC on dried blood spots collected shortly after birth. The newborn screening pattern "FS" indicates sickle cell disease with fetal hemoglobin and sickle hemoglobin but no adult hemoglobin A. Pattern "FAS" indicates sickle cell trait with fetal hemoglobin, adult hemoglobin A, and sickle hemoglobin. Pattern "F only" without adult hemoglobin suggests beta-thalassemia major where beta-globin production is absent. Positive screening results require confirmatory testing and family studies, along with genetic counseling regarding implications and follow-up care. Genetic counseling provides essential information for family planning when one or both partners carry hemoglobin gene mutations. Two carriers of sickle cell trait have a 25 percent chance of having a child with sickle cell disease, 50 percent chance of trait, and 25 percent chance of normal hemoglobin with each pregnancy. Carrier testing of partners allows informed reproductive decision-making. Prenatal diagnosis through chorionic villus sampling or amniocentesis with DNA analysis identifies affected fetuses, allowing parents to prepare for a child with special medical needs or consider pregnancy termination. Preimplantation genetic diagnosis with in vitro fertilization allows selection of unaffected embryos. Extended family screening may identify additional carriers who would benefit from counseling. For thalassemia, carrier identification is particularly important in populations with high prevalence, where both partners being carriers creates 25 percent risk of thalassemia major. Panel A: Hemoglobin electrophoresis patterns comparing normal adult, sickle cell trait, sickle cell disease, beta-thalassemia trait, and beta-thalassemia major showing band positions and percentages of each hemoglobin type. Panel B: Iron studies comparison showing characteristic patterns in iron deficiency versus thalassemia trait with ferritin, iron, TIBC, and transferrin saturation values. Panel C: Newborn screening workflow from initial collection through testing, reporting, confirmatory testing, and counseling with interpretation of common patterns. Panel D: Genetic counseling diagram showing inheritance probabilities from two carriers with decision points for prenatal testing and reproductive options. --- ## Summary - Hemoglobin structure consists of alpha-2-beta-2 tetramers in normal adult hemoglobin A, with cooperative oxygen binding producing the sigmoidal dissociation curve - Sickle cell disease results from the beta-6 glutamic acid to valine mutation causing hemoglobin S polymerization when deoxygenated - Vaso-occlusive crises cause severe bone pain, acute chest syndrome, and stroke through sickled cell adhesion and microvascular occlusion - Acute chest syndrome is the leading cause of death requiring aggressive supportive care, antibiotics, and often exchange transfusion - Hydroxyurea is the primary disease-modifying therapy, inducing fetal hemoglobin that does not participate in sickling - Transfusion therapy provides acute treatment and chronic prevention of complications, with exchange transfusion for severe events - Thalassemias result from reduced globin chain production causing imbalanced synthesis and ineffective erythropoiesis - Alpha-thalassemia severity ranges from silent carrier through trait to hemoglobin H disease and lethal Barts hydrops fetalis based on number of deleted genes - Beta-thalassemia major requires chronic transfusion and iron chelation, with curative options including transplant and gene therapy - Beta-thalassemia trait shows microcytosis disproportionate to mild anemia with elevated hemoglobin A2, distinguishing it from iron deficiency --- ## Key Terms | Term | Definition | |------|------------| | Hemoglobin S | Sickle hemoglobin with beta-6 glutamic acid to valine substitution causing polymerization when deoxygenated | | Vaso-occlusive crisis | Acute episode of severe pain from tissue ischemia caused by sickled cells obstructing microvasculature | | Acute chest syndrome | Life-threatening pulmonary complication with new infiltrate and respiratory symptoms requiring urgent treatment | | Hydroxyurea | Disease-modifying therapy inducing fetal hemoglobin production and reducing sickle cell complications | | Thalassemia | Inherited disorder of reduced globin chain synthesis causing anemia from ineffective erythropoiesis | | Ineffective erythropoiesis | Intramedullary destruction of erythroid precursors before maturation due to precipitation of excess unpaired globin chains | | Hemoglobin A2 | Minor adult hemoglobin with alpha-2-delta-2 composition elevated in beta-thalassemia trait above 3.5 percent | | Iron chelation | Therapy with deferoxamine, deferasirox, or deferiprone to remove excess iron accumulated from chronic transfusion | --- *This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*